What is the recommended dose of tranexamic acid (TXA) for a female patient of reproductive age with menorrhagia and no history of thromboembolic events?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tranexamic Acid Dosing for Menorrhagia

For menorrhagia (heavy menstrual bleeding) in reproductive-age women without thromboembolic history, the recommended dose is 1.3 grams orally three times daily (total 3.9 grams/day) for up to 5 days during menstruation, starting on the first day of bleeding. 1, 2

Standard Dosing Regimen

The evidence-based oral dosing for idiopathic menorrhagia is:

  • Total daily dose: 3.9-4 grams per day 1
  • Divided dosing: 1-1.5 grams three times daily 2, 3
  • Duration: 4-5 days per cycle, starting from day 1 of menstruation 1, 2
  • Alternative regimen: 1 gram four times daily for 4 days 2, 4

This dosing reduces menstrual blood loss by 34-59% compared to baseline, which is significantly superior to NSAIDs, oral progestins, or placebo. 1, 2

Clinical Efficacy Context

Tranexamic acid works by competitively inhibiting plasminogen activation, thereby preventing fibrin degradation and stabilizing clots. 5, 1 In comparative trials:

  • More effective than: mefenamic acid, flurbiprofen, etamsylate, and luteal phase norethisterone 2, 3
  • Less effective than: levonorgestrel-releasing IUD (which reduces bleeding by 96% but causes amenorrhea in 44% of users) 3
  • Patient satisfaction: 81% of women report satisfaction, with 94% noting decreased menstrual blood loss 2

Absolute Contraindications

Do not prescribe tranexamic acid if the patient has: 5, 1

  • Active thromboembolic disease
  • History of thrombosis or thromboembolism
  • Intrinsic risk factors for thrombosis or thromboembolism

The patient described has no thromboembolic history, making tranexamic acid appropriate.

Important Clinical Distinctions

This menorrhagia dosing is completely different from post-partum hemorrhage dosing. 5 The post-partum regimen uses 1 gram IV over 10 minutes (not oral), must be given within 3 hours of birth, and is time-critical for mortality benefit. 6, 5 Do not confuse these two distinct clinical scenarios—menorrhagia is a chronic outpatient condition requiring oral therapy during menses, while post-partum hemorrhage is an acute emergency requiring immediate IV administration.

Safety Profile

Adverse effects are predominantly mild gastrointestinal symptoms (nausea, vomiting, diarrhea, dyspepsia) occurring in approximately 12% of patients, which is not significantly different from placebo rates. 2 Importantly, no evidence exists of increased thrombotic events with tranexamic acid use for menorrhagia at recommended doses. 1

Practical Implementation

  • Start therapy on the first day of menstrual bleeding 1
  • Continue for 4-5 consecutive days only (not throughout the entire cycle) 1, 2
  • Reassess after 2-3 cycles to evaluate efficacy 2
  • Consider alternative therapy if bleeding remains unacceptable after trial period 6

Common Pitfalls to Avoid

Do not prescribe tranexamic acid continuously throughout the menstrual cycle—it should only be taken during days of active bleeding. 1, 2 This is a frequent prescribing error that increases cost and potential side effects without additional benefit.

Do not withhold tranexamic acid while waiting for hormonal therapy to take effect if the patient desires immediate pregnancy or has contraindications to hormonal treatment. 7 Tranexamic acid is particularly valuable in these scenarios as it does not interfere with fertility.

References

Guideline

Tranexamic Acid Dosing for Uterine Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tranexamic acid therapy for heavy menstrual bleeding.

Expert opinion on pharmacotherapy, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.